Trials / Completed
CompletedNCT01385657
Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous REGN668 in Patients With Moderate-to-Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | A total of 4 doses were administered. |
| DRUG | Dupilumab | A total of 4 doses were administered. |
| OTHER | Background treatment | Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study. |
Timeline
- Start date
- 2011-07-31
- Primary completion
- 2012-03-31
- Completion
- 2012-03-31
- First posted
- 2011-06-30
- Last updated
- 2020-02-26
Locations
13 sites across 3 countries: Australia, Germany, New Zealand
Source: ClinicalTrials.gov record NCT01385657. Inclusion in this directory is not an endorsement.